KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) EBIAT (2016 - 2025)

Travere Therapeutics' EBIAT history spans 15 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, EBIAT rose 104.46% year-over-year to $2.7 million; the TTM value through Dec 2025 reached -$25.5 million, up 92.08%, while the annual FY2025 figure was -$25.5 million, 92.06% up from the prior year.
  • EBIAT reached $2.7 million in Q4 2025 per TVTX's latest filing, down from $25.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $25.7 million in Q3 2025 to a low of -$136.1 million in Q1 2024.
  • Average EBIAT over 5 years is -$61.4 million, with a median of -$67.7 million recorded in 2022.
  • Peak YoY movement for EBIAT: plummeted 6766.71% in 2021, then surged 146.95% in 2025.
  • A 5-year view of EBIAT shows it stood at -$88.8 million in 2021, then increased by 25.85% to -$65.8 million in 2022, then tumbled by 34.6% to -$88.6 million in 2023, then surged by 30.94% to -$61.2 million in 2024, then skyrocketed by 104.46% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's EBIAT are $2.7 million (Q4 2025), $25.7 million (Q3 2025), and -$12.8 million (Q2 2025).